BiotechTV - News

CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in numerous prestigious pharma partnerships.

Co-Founder and CEO Pete Smith describes how Remix uses small molecules to stop the transcription of disease causing mRNAs. The lead program targets MYB and is in a phase 1/2 for adenoid cystic carcinoma. The reverse merger could close towards the end of year.

Interviewed by MassBio CEO Kendalle Burlin O'Connell, Ilan Ganot describes co-founding Solid Biosciences in honor of his child with Duchenne muscular dystrophy and Daniel Fischer discusses co-founding Tevard Biosciences in honor of his child with Dravet syndrome.

Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well.

Dr. Berger, who founded Ariad Pharmaceuticals here in 1991, describes Kendall's transition from candy factories, to Polaroid, to what it is today.

Jim Olaghere describes signing up for a gene editing treatment clinical trial for sickle cell disease and how it has enabled him to climb mountains and Bob Coughlin recounts the moment when a therapy became available for his son's cystic fibrosis.

Alexis Borisy recounts the story of Revolution Medicines, which delivered the pancreatic cancer breakthrough this year, and talks about the health of the founder led side of the biotech sector. Mathai Mammen recently took Parabilis public in the largest IPO in biotech history, and describes the science that made it possible.

He describes how science 'keeps you young' because it always based on what you don't know. He urges scientists to stay humble when talking about science to the public because things can change, and he shares stories from his career and offers advice on how to keep the United States globally competitive.

Interviewed by HSBC Innovation Banking's Katherine Andersen, Najat Khan discusses AI, her priorities upon taking the role of CEO at Recursion earlier this year, encouraging employees to speak more than just one language of expertise, and women in leadership.

Moderated by BiotechTV's Chloe Kirk, Gabriel Astorga (@GoodOlGab), Maynard Okereke (@HipHopScienceShow), and Alex Dainis (@AlexDainis) describe how the got started posting about science on social media and how they grew their audiences to what they are today. Plus, advice for companies and scientists about how to resonate the best.